President Bush intends to appoint John Niederhuber as the National Cancer Institute’s 13th director, the National Institutes of Health said this week in a statement.
Niederhuber was named acting director for the institute in June. He is also involved in research at the Laboratory of Tumor and Stem Cell Biology, part of the cell and cancer biology branch of NCI’s Center for Cancer Research. Niederhuber is also on the NIH Clinical Center’s medical staff.
Prior to becoming acting director, he was NCI's chief operating officer and deputy director for translational and clinical sciences. Prior to that he was chair of the National Cancer Advisory Board.
Niederhuber was a professor of surgery and oncology at the University of Wisconsin School of Medicine in Madison and director of the University of Wisconsin Comprehensive Cancer Center.
Niederhuber also chaired the department of surgery at Stanford University and was a professor at the Johns Hopkins University School of Medicine and at the University of Michigan.
Rich Keffer joined Sigma-Aldrich as corporate vice-president, general counsel, and secretary, the company said Tuesday.
His appointment is effective Aug. 28.
Keffer comes to Sigma-Aldrich from D&K Healthcare, which was acquired by McKesson in 2005. He has 25 years of corporate legal experience from companies in the consumer products, chemical and pharmaceutical industries.
Keffer received his JD degree from Washington University School of Law and a BA in economics from Greenville College.
Gene Logic named three new executives in its preclinical division’s toxicology services last week.
James R. Szabo was promoted to vice-president of toxicology services and C. Steven Godin was promoted to senior director of general toxicology.
Kory Engelke joined the company as senior director of general toxicology.
Prior to joining Gene Logic in 2004, Szabo was at Dow Chemical and lectured at the University of Houston. He was a research associate and teaching associate at the University of Illinois and had a private veterinary practice. He holds a D.V.M. and a Ph.D. in pathology from the University of Illinois.
Prior to joining Gene Logic in 2004, Godin was a senior study director at MPI Research, director of toxicology at White Eagle Toxicology Laboratories, manager of drug metabolism at Cephalon, and project scientist for ManTech Environmental. Godin holds a Ph.D. in pharmaceutical sciences from the University of Kentucky.
Engelke joined Gene Logic from Sucampo Pharmaceuticals. Prior to Sucampo, he was with Guilford Pharmaceuticals and Battelle Memorial Institute in the pharmaceutical product division. Engelke holds a Ph.D. in pharmacology from the University of Vermont and was a post-doctoral fellow at Battelle Pulmonary Therapeutics and Ohio State University.